

Original Article

Neutrophilic Steroid-Refractory Recurrent Wheeze and Eosinophilic Steroid-Refractory Asthma in Children

Tamazoust Guiddir, MD^{a,b}, Philippe Saint-Pierre, PhD^c, Elsa Purenne-Denis, MD^a, Nathalie Lambert, MD^{a,b}, Yacine Laoudi, MD^a, Rémy Couderc, PhD, PharmD^d, Rahelé Gouvis-Echraghi, MD^a, Flore Amat, MD^{a,b}, and Jocelyne Just, MD, PhD^{a,b} Paris and Toulouse, France

What is already known about this topic? In preschool children, recurrent wheezes have a good prognosis but severe phenotypes exist. At school age, severe asthma is often associated with multiple allergies. In these 2 cases, the physiopathological pathways are not well known.

What does this article add to our knowledge? Inflammatory cells and different triggers are associated with 2 phenotypes of severe obstructive diseases during childhood: neutrophils and bacterial infection in preschool children and eosinophils and multiple allergies at school age.

How does this study impact current management guidelines? These 2 severe childhood obstructive diseases—neutrophilic steroid-refractory recurrent wheeze and eosinophilic steroid-refractory asthma—could be treated by targeted therapies such as antibiotic and T helper lymphocyte type 2 biotherapy directed towards neutrophil and eosinophil inflammation, respectively.

BACKGROUND: Little is known about inflammatory pathways of severe recurrent wheeze in preschool children and severe asthma in children.

OBJECTIVES: The aim of the Severe Asthma Molecular Phenotype cohort was to characterize phenotypes of severe recurrent wheeze and severe asthma during childhood in terms of triggers (allergic or not), involved cells (eosinophil or neutrophil), and corticoid responsiveness.

METHODS: Children with moderate-to-severe asthma and preschool children with moderate-to-severe recurrent wheeze were enrolled prospectively. They underwent standardized clinical and blood workup, and bronchoalveolar lavage (BAL) evaluation. Cluster analysis was applied to 350 children with 34 variables.

RESULTS: Three clusters were identified: cluster 1, *Neutrophilic steroid-refractory recurrent wheeze phenotype*, with 138 children uncontrolled despite high-dose inhaled corticosteroids (ICS) (92%, $P < .001$), with more history of pneumonia (31%, $P < .001$), more gastroesophageal reflux disease (37%, $P < .001$), and the highest blood neutrophil count (mean 4.524 cells/mm³,

$P = .05$); cluster 2, *Severe recurrent wheeze with sensitization to a single aeroallergen* (12%, $P = .002$), with 104 children controlled with high-dose ICS (63%, $P < .001$); cluster 3, *Eosinophilic steroid-refractory asthma phenotype*, with 108 children uncontrolled despite high-dose ICS (76%, $P < .001$) with more allergic rhinitis, atopic dermatitis, and food allergies (82%, 40%, 31%, $P < .001$, respectively). They also had a higher blood eosinophil count and a higher percentage of BAL eosinophil (506/mm³, 2.6%, $P < .001$ respectively).

CONCLUSIONS: Inflammation pathway of asthma and recurrent wheeze are related to eosinophil cells in older children and neutrophil cells in younger children. These results could improve personalized treatments. © 2017 American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2017;■:■-■)

Key words: Severe asthma; Severe recurrent wheeze phenotypes; Children; Bacterial infection; Gastroesophageal reflux; Multiple allergies

^aAllergology Department, Armand Trousseau Children Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

^bUniversity Paris 06, Sorbonne University, Paris, France

^cInstitute of Mathematics, Toulouse III Paul-Sabatier University, Toulouse, France

^dBiochemistry Laboratory, Armand Trousseau Children Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

No funding was received for this work.

Conflicts of interest: T. Guiddir has received lecture fees from Novartis and Mead Johnson. F. Amat has received lecture fees from Novartis, ALK, and Mead Johnson. J. Just is on the boards for ALK Abello, Stallergenes Green, AstraZeneca, and Novartis; and has received research support from Novartis. The rest of the authors declare that they have no relevant conflicts of interest.

Received for publication September 15, 2016; revised January 21, 2017; accepted for publication February 3, 2017.

Available online ■■

Corresponding author: Jocelyne Just, MD, PhD, Centre de l'Asthme et des Allergies, Groupe hospitalier Trousseau-La Roche Guyon, 26 Avenue du Dr. Arnold Netter, 75012 Paris, France. E-mail: jocelyne.just@aphp.fr.

2213-2198

© 2017 American Academy of Allergy, Asthma & Immunology

<http://dx.doi.org/10.1016/j.jaip.2017.02.003>

Abbreviations used

BMI- Body mass index
 FP- Fluticasone propionate
 GERD- Gastroesophageal reflux
 ICS- Inhaled corticosteroid
 LTRA- Leukotriene receptor antagonist
 MTW- Multiple-trigger wheeze
 SAMP- Severe Asthma Molecular Phenotype
 SARP- Severe Asthma Research Program
 SPT- Skin prick test
 TAP- Trousseau Asthma Program

Asthma is a heterogeneous disease related to various phenotypes. Severe asthma is rare but represents a high burden of the disease. Two pathophysiological pathways of asthma can be described in terms of the principal triggers: allergic and nonallergic.¹ However, in 1999, Humbert et al² found IgE in bronchial biopsies of patients tested negative for allergy. These results contest the dichotomous feature of *extrinsic* and *intrinsic* asthma. Moreover, it seems that in birth cohorts, allergic asthma conveys the highest risk of persistence during childhood.³ Nevertheless, nonallergic asthma (with predominance in girls) seems to be more common and more severe than allergic asthma in cohorts of children with asthma⁴ than in adult patients.^{5,6} This difference could be due to the fact that the nonallergic asthma phenotype is not considered as a phenotype of asthma in the general population but related to viral-induced wheeze carrying with it the notion of a favorable disease course or remission during childhood.

The term “recurrent persistent wheeze” is applied to infants and preschool age children who present with recurrent episodes of coughing and/or wheezing. Although these symptoms are common in the preschool years, they are frequently transient.⁷ Bacharier et al⁸ described a phenotype of severe intermittent wheezing in preschool children where children with oral corticosteroid used in the previous year were likely to have more severe disease, documented by a higher incidence of visits to the emergency department, hospitalizations, and aeroallergen sensitization. Severe recurrent preschool wheeze is also defined by Fleming et al⁹ as a history of breathlessness and wheeze and persistent symptoms and/or frequent severe exacerbation despite a combination of high-dose inhaled corticosteroid (ICS) with a leukotriene receptor antagonist (LTRA). Although the underlying mechanisms are not yet known, some of these preschool children have evidence of airway remodeling and inflammation.¹⁰ Some of them, especially those with severe recurrent wheeze, will also develop asthma during childhood.¹¹ Indeed, a retrospective analysis of a cohort of severe asthma in children aged more than 6 years (Severe Asthma Research Program [SARP] cohort) suggests that many school-age children with severe asthma have symptoms that appeared within the first 24 months of life.¹² At the time of the development of various biotherapies directed against T helper lymphocyte type 2 (Th2) or T helper lymphocyte type 1 pathways for the treatment of severe asthma,¹³ it could also be interesting to describe severe asthma in children and severe recurrent wheeze in preschool children (potentially at risk of persistence) as regards the triggers and link to atopy, but also in terms of inflammatory features and corticoid responsiveness.^{11,14,15}

We therefore performed a study in a new population of the Trousseau Asthma Program (TAP) called the Severe Asthma Molecular Phenotype (SAMP) cohort, to characterize preschool recurrent wheeze phenotypes and severe asthma in children.

METHODS**Design and setting**

This was a prospective cross-sectional study performed from 2011 to 2015 from SAMP, a part of the TAP cohort, at Trousseau Hospital, Paris. All the children had been referred to the center by a primary care physician because of persistence of recurrent wheeze despite long-term treatment. Two-thirds of the children were from Paris and the surrounding area, and the remaining third were from all regions of France. The Institutional Review Board of Saint Antoine Hospital, Paris, endorsed the protocol as an observational study. Written informed consent was obtained from the parents of the children included.

Inclusion criteria

The population included in the present study consisted of children meeting the following inclusion criteria: (i) children with severe asthma or severe recurrent wheeze (as defined below) aged from 1 to 15 years at the time of exploration; (ii) who had undergone exploration at least 6 weeks after an episode of exacerbation, acute respiratory illness or treatment by antibiotics; (iii) had a history of recurrent wheeze (more than 3 episodes of bronchodilator reversible bronchial obstruction documented within the previous 6 months); (iv) had been explored by flexible bronchoscopy for severe asthma, severe recurrent wheeze, moderate recurrent wheeze, or moderate asthma with unusual symptoms (ie, cough with phlegm associated with wheezing, and/or persistent parenchymal shadowing); (v) for whom other diseases known to provoke wheezes had been ruled out by flexible bronchoscopy and bronchoalveolar lavage (BAL) with microbiological analysis consisting of bacterial cultures and viral analysis (PCR for influenza (A and B), parainfluenzae (1, 2, 3), metapneumovirus); available blood-cell count, IgG, IgM, IgA blood levels, post-vaccine tetanus and diphtheria serologies; and a sweat test. In the rare cases of bronchiectasis and/or chronic severe ear or sinus disorders, a bronchial biopsy/brushing was performed to rule out a primary ciliary pathology. Definitions of asthma in children: (i) moderate asthma was defined as controlled asthma or partially controlled asthma with moderate dose ICS (≥ 200 and < 500 mcg/day fluticasone propionate [FP]) plus another controller medication (LTRA, long-acting β -agonist); (ii) severe asthma was defined as controlled asthma with high-dose ICS (≥ 500 mcg/day FP) and 2 other controller medications; and (iii) steroid-refractory asthma was defined as uncontrolled asthma despite high-dose ICS (≥ 500 mcg/day FP) and 2 other controller medications according to GINA guidelines¹⁶ and dosage for fluticasone available in France.

Definitions of asthma in preschool children: (i) moderate recurrent wheeze was defined as controlled or partially controlled symptoms with moderate-dose ICS (≤ 200 mcg/day FP) and LTRA⁹; (ii) severe recurrent wheeze was defined as controlled symptoms with high-dose ICS (> 200 mcg/day) and LTRA; and (iii) steroid-refractory recurrent wheeze was defined as uncontrolled symptoms (persistent and frequent exacerbations) despite high-dose ICS (> 200 mcg/day) and LTRA.⁹ The severity of asthma or recurrent wheeze of the entire population was assessed after at least 6 months of follow-up before inclusion in the study, by an experienced pulmonologist pediatrician after repeated individual or group health education measures to improve adherence to antiasthmatic treatment and after

advice by an environmental specialist to reduce exposure to indoor biological pollutants.

Totally controlled asthma was defined as any nocturnal or daily symptoms, any exacerbation, any use of short-acting β_2 -agonist, any activity limitation due to asthma, and partially or uncontrolled asthma as presence of 1-2 or 3-4 of previous parameters respectively.¹⁶

Health outcomes were collected in a computerized database using questionnaires and clinical examinations following a standardized protocol. Gender, body mass index (BMI) (weight/height²), and ethnic group and parents' socioprofessional categories were recorded.

The age of wheeze onset was defined as the time of the first episode of obstructive symptoms.

Children were classified as having either episodic viral wheeze (wheezing only during colds and remaining asymptomatic between episodes) or multiple-trigger wheeze (MTW) (wheezing during colds but symptomatic between episodes with wheezing activated by dust, grass, pets, tobacco smoke, exercise, or cold air).

Atopic status

The maternal and paternal history of asthma was collected. Allergic rhinitis and active atopic dermatitis were assessed by questions from the International Study of Asthma and Allergies in Childhood,¹⁷ and IgE-mediated food allergy was defined by relevant symptoms of food allergy within the 6 hours after consumption of the food allergen associated with an allergic sensitization to the same allergen.¹⁸

Standard skin prick test (SPT), Phadiatop Infant test, and serum-specific IgE levels for current allergens and staphylococcal toxins were assessed (see this article's Online Repository at www.jaci-inpractice.org). We defined sensitization as positive SPT as well as positive specific IgE to ensure an accurate diagnosis. Perennial sensitization only was defined as sensitization to house dust mite and/or cat or dog dander without seasonal sensitization. Seasonal sensitization was defined as sensitization to grass and/or birch pollens only, without perennial sensitization.

Comorbidities

Gastroesophageal reflux disease (GERD) was defined as the presence of suggestive symptoms or pathological 24-hour oesophageal pH-metry or good response to therapy.¹⁹

A history of pneumonia was defined as a medical diagnosis of a history of fever and cough or breathing distress associated with alveolar syndrome on chest X-ray.²⁰ The number of antibiotic treatments for pneumonia history in the previous year was noted and classified into 3 categories: children having (1) 0 to 3 treatments, (2) 3 to 12 treatments, and (3) more than 12 treatments.

Flexible bronchoscopy

Flexible bronchoscopy was performed under local anesthesia, as previously described, in our center, in which more than 300 flexible bronchoscopies are routinely performed a year.²¹ Children received intrarectal midazolam and atropine with nitrous oxide (Entonox) during the bronchoscopy. BAL was collected²² and processed for cytology by the hospital cytopathology department.

Microbiological cultures of BAL

Aliquots of BAL were systematically used for microbiological assessment with bacterial cultures and viral analysis (PCR for influenza (A and B), parainfluenza (1, 2, 3), metapneumovirus). Positive bacterial culture was defined as positive if growth was $\geq 10^4$ colony-forming units (CFU)/mL.²³




FIGURE 1. Scatter plot of the first 2 principal coordinates, which display the 3 clusters identified with Ward's method ($n = 350$). The 2 principal coordinates obtained captured 12% and 7% of the total variance. Each point represents a single subject. The plot depicts clustering and clear separation of children with neutrophilic steroid-refractory recurrent wheeze in young children ($n = 138$) (blue circles), severe recurrent wheeze with sensitization to aeroallergen only in children ($n = 104$) (red circles), and eosinophilic steroid-refractory asthma with multiple allergies in children ($n = 108$) (green circles).

Inflammatory markers

Blood eosinophilia and serum total IgE were collected. Nonspecific blood inflammatory markers included neutrophil cell count and serum IgG, IgA, and IgM levels (see this article's Online Repository at www.jaci-inpractice.org). Eosinophil and neutrophil cells in BAL were expressed as a percentage of the total cell count.

Statistical analysis

Statistical analysis was performed with R version 2.12.0 (<https://www.r-project.org>; R Core Team, Vienna, Austria) (see this article's Online Repository at www.jaci-inpractice.org). The 34 selected variables were analyzed using an unsupervised classification approach to find groups of patients in the study population. The variables were: (1) age at the time of exploration; (2) age of asthma onset; (3) >75th percentile BMI; (4) gender; (5) parents' socioprofessional categories; (6) ethnic group; (7) maternal history of asthma; (8) paternal history of asthma; (9) history of pneumonia; (10) history of GERD; (11) active allergic rhinitis; (12) active atopic dermatitis; (13) IgE-mediated food allergy; (14) more than 2 hospitalizations for severe exacerbation during the previous year; (15) wheezing triggers; (16) annual number of antibiotics for pneumonia; (17) asthma severity; (18) perennial sensitization only; (19) seasonal sensitization only; (20) both sensitization to perennial and seasonal allergens; (21) sensitization to egg and/or cow's milk proteins; (22) peanut sensitization; (23) *Alternaria alternata* sensitization; (24) staphylococcal toxin sensitization; (25) Phadiatop Infant test ≥ 0.35 kU/L; (26) absolute value of blood neutrophil; (27) absolute value of blood eosinophil; (28) serum total IgE (kU/L); (29) IgG level (g/L); (30)

TABLE I. Patients' characteristics according to the entire population

	Preschool recurrent wheeze (n = 217)	Asthma in children (n = 133)	P value
Demographic details			
Gender, male n (%)	148 (68)	89 (66)	.89
Age, mo; mean (SD)	33.9 (21.9)	138 (22.5)	<.01
Exposure to tobacco, n (%)	80 (36)	38 (29)	.14
Low socioeconomic categories of parents, n (%)	96 (44)	60 (45)	.62
Ethnic origin, n (%)			.01
Caucasian	172 (79)	92 (69)	
African	43 (20)	32 (24)	
Indian	2 (1)	8 (6)	
Asian	0 (0)	1 (1)	
Anthropometry			
BMI, % (SD)	16.4 (2.0)	19 (4)	<.01
Personal atopy			
Atopic dermatitis, n (%)	68 (31)	64 (48)	.002
Allergic rhinitis, n (%)	71 (33)	92 (69)	<.01
IgE-mediated food allergy, n (%)	26 (12)	27 (20)	.08
Familial atopy			
Maternal asthma, n (%)	53 (24)	30 (22)	.75
Paternal asthma, n (%)	40 (18)	30 (22)	.45
Asthma history			
Age at wheeze onset months, mean (SD)	7.7 (12.5)	19.9 (25.0)	<.01
Single trigger wheeze, n (%)	156 (72)	59 (44)	<.01
Multiple trigger wheeze, n (%)	61 (28)	74 (55)	<.01
>2 hospitalizations for severe exacerbation, n (%)	37 (17)	10 (7)	.01
Asthma severity			
			.37
Moderate, n (%)	34 (16)	26 (20)	
Severe, n (%)	183 (84)	107 (80)	
Severe asthma control			
			.16
Controlled with high-dose ICS, n (%)	56 (26)	47 (35)	
Uncontrolled with high-dose ICS, n (%)	127 (59)	86 (65)	
Blood inflammation			
Blood PN, mean (SD)	4429 (2912) (n = 213)	3460 (2098) (n = 122)	<.01
Blood PE, mean (SD)	273 (325) (n = 213)	432 (378) (n = 122)	<.01
IgG level, mean (SD)	6.9 (2.2) (n = 188)	9.9 (2.2) (n = 122)	<.01
IgA level, mean (SD)	0.6 (0.4) (n = 188)	1.5 (0.7) (n = 122)	<.01
IgM level, mean (SD)	1.0 (0.8) (n = 188)	1.0 (0.5) (n = 122)	<.01
BAL cells			
BAL PN, mean (SD)	7.0 (10.6) (n = 209)	4.9 (7.5) (n = 113)	.01
BAL PE, mean (SD)	0.7 (2.2) (n = 209)	2 (5.5) (n = 113)	<.01
Allergic sensitization			
Positive Phadiatop Infant test, n (%)	59 (27) (n = 214)	102 (77) (n = 132)	<.01
Perennial sensitization only, n (%)	30 (14) (n = 214)	1 (1) (n = 132)	<.01
Seasonal sensitization only, n (%)	2 (1) (n = 214)	3 (2) (n = 132)	1
Perennial and seasonal sensitization, n (%)	3 (1) (n = 214)	52 (39) (n = 132)	<.01

(continued)

TABLE I. (Continued)

	Preschool recurrent wheeze (n = 217)	Asthma in children (n = 133)	P value
<i>Alternaria alternata</i> sensitization, n (%)	1 (0.4) (n = 214)	30 (22) (n = 132)	<.01
Peanut sensitization, n (%)	6 (3) (n = 214)	20 (15) (n = 132)	<.01
Cow's milk and/or egg sensitization, n (%)	28 (13) (n = 214)	25 (21) (n = 132)	.19
Staphylococcal toxins sensitization, n (%)	17 (9) (n = 191)	46 (35) (n = 121)	<.01
Nonallergic comorbidities			
History of pneumonia, n (%)	68 (31)	20 (15)	<.01
GERD, n (%)	85 (39) (n = 214)	29 (22) (n = 133)	<.01
BAL microbiology			
Negative, n (%)	158 (73) (n = 215)	112 (84) (n = 131)	<.01
Positive, n (%)	57 (26)	19 (14)	

BAL: Bronchoalveolar lavage; Blood PE, blood eosinophil cells; Blood PN, blood neutrophil cells; BMI, body mass index; ICS, inhaled corticosteroid; GERD, gastroesophageal reflux disease.

IgA level (g/L); (31) IgM level (g/L); (32) BAL neutrophil percentage; (33) BAL eosinophil percentage; (34) BAL microbiological cultures.

A hierarchical bottom-up clustering was applied using the R package “cluster.”²⁴ The Gower distance was considered because quantitative and categorical variables are involved in the cluster analysis. By definition, this distance implies that standardization is applied to each variable, avoiding scaling bias. Ward's linkage that minimizes the within-cluster sum of squares was considered.²⁵ The number of clusters was chosen at the end of the procedure using the scree plot of the distance of merging clusters. In our case, 3 clusters clearly emerged. The dissimilarity matrix was then visualized in a low-dimensional space (Figure 1) using a classical multidimensional scaling.²⁵ Besides, a factor analysis for mixed data²⁶ was applied to identify the variables involved in the first 2 principal components. For each variable, the difference between clusters was evaluated using ANOVA and the Kruskal-Wallis test for continuous variables and a χ^2 test and Fisher exact test for categorical variables.

RESULTS

Patients

The study initially considered 355 children for inclusion. Of these, 5 were not retained for the following reasons: (i) 2 had a lung malformation, (ii) 2 had positive viral analysis in BAL, and (iii) more than 3 parameters were missing for the cluster analysis for 1. Thus, the final study population consisted of 350 children, 237 (64.4%) of whom were boys. Twenty-eight children have missing BAL cell data (Table I). No severe complication was detected after the bronchoscopy. Transient desaturation was observed in 10 children. Detailed characteristics of the entire population (preschool children aged less than 72 months and children aged more than 72 months) are shown in Table I.

Asthma phenotypes according to cluster analysis

Cluster analysis produced a dendrogram (Figure 2) and a scatter plot (Figure 1) that reveal 3 clusters of children with shared phenotypic characteristics (Tables II-IV). Factor analysis indicates that age, eosinophils, and Phadiatop Infant test play an important role for principal component 1, whereas asthma




FIGURE 2. Dendrogram for the entire population (n = 350) obtained by using a hierarchic bottom-up clustering method. Three clusters emerged.

control and asthma severity are the main factors involved in principal component 2. Figure 3 represents blood cell inflammation and severity of asthma according to the 3 clusters.

Cluster 1. This cluster comprised 138 children (Table II) with early onset of wheeze at an average age of 6.8 months ($P < .001$) (Table II). Severe recurrent wheeze represented 94% of the cluster ($P < .001$) and was uncontrolled despite high-dose ICS (92%, $P < .001$) (Table II). Wheezing triggers were principally viral induced (75%, $P < .001$) (Table II). These children had more nonallergic comorbidities such as history of pneumonia (31%, $P < .001$) and were more likely to have a history of GERD (37%, $P < .001$) than children of the other clusters (Table III). The BAL bacterial cultures were significantly more positive (26%, $P < .001$) in this cluster, with a predominance of *Haemophilus influenzae* and *Branhamella catarrhalis* (Table III). Thirty percent of the children in this cluster had more than 4 antibiotic treatments annually ($P < .001$) (Table III). This phenotype was mostly nonallergic with a negative Phadiatop Infant test in 85% of the cases ($P < .001$) (Table III). It was also associated with the highest blood neutrophil count (mean 4.524

TABLE II. Patients' and asthma characteristics according to cluster analysis

	Entire population (N = 350)	Cluster 1: Neutrophilic steroid-refractory recurrent wheeze phenotype (n = 138)	Cluster 2: Severe recurrent wheeze with sensitization to a single aeroallergen (n = 104)	Cluster 3: Eosinophilic steroid-refractory asthma phenotype (n = 108)	P value*
Patient's characteristics					
Gender, male; n (%)	237 (68)	98 (71)	72 (69)	67 (62)	.30
Age, mo; mean (SD)	73.6 (57.8)	40.6 (39.2)	57.3 (39.8)	131.3 (49.0)	<.001
BMI,† n (%)	88 (25)	22 (16)	14 (13)	52 (35)	<.001
Low socioeconomic categories of parents, n (%)	156 (46)	59 (44)	53 (53)	44 (41)	.51
Ethnic origin, n (%)					.07
Caucasian	264 (75)	113 (82)	74 (71)	77 (71)	
African	75 (21)	22 (16)	28 (27)	25 (23)	
Indian	10 (3)	3 (2)	1 (1)	6 (6)	
Asiatic	1 (0.3)	0 (0)	1 (1)	0 (0)	
Maternal asthma, n (%)	83 (24)	33 (24)	20 (19)	30 (28)	.36
Paternal asthma, n (%)	70 (20)	28 (20)	13 (13)	29 (27)	.03
Asthma characteristics					
Age at wheeze onset, mo; mean (SD)	12.3 (19.3)	6.8 (6.9)	11.6 (19.7)	19.9 (26.0)	<.001
Moderate asthma or moderate recurrent wheeze, n (%)	60 (17)	8 (6)	37 (36)	15 (14)	<.001
Severe asthma or severe recurrent wheeze, n (%)	290 (83)	130 (94)	67 (64)	93 (86)	
Controlled asthma or controlled recurrent wheeze with high-dose ICS, n (%)	77 (22)	3 (2)	63 (61)	11 (10)	<.001
Uncontrolled asthma or uncontrolled recurrent wheeze with high-dose ICS, n (%)	213 (61)	127 (92)	4 (4)	82 (76)	
>2 hospitalizations for severe exacerbation, n (%)	47 (13)	24 (17)	11 (11)	12 (11)	.21
Triggers, n (%)					<.001
EVW	215 (61)	103 (75)	75 (72)	37 (34)	
MTW	135 (39)	35 (25)	29 (28)	71 (66)	

BMI, Body mass index; EVW, episodic viral wheeze; ICS, inhaled corticosteroid; MTW, multiple trigger wheezes.

Boldface values indicate statistical significance.

*ANOVA or χ^2 test when conditions were respected; the Kruskal-Wallis or Fisher exact test otherwise.

†BMI is expressed as the number of children with values equal to or above the 75th percentile.

TABLE III. Allergic and nonallergic comorbidities according to cluster analysis

	Entire population (N = 350)	Cluster 1: Neutrophilic steroid-refractory recurrent wheeze phenotype (n = 138)	Cluster 2: Severe recurrent wheeze with sensitization to a single aeroallergen (n = 104)	Cluster 3: Eosinophilic steroid-refractory asthma phenotype (n = 108)	P value*
Allergic comorbidities					
Active atopic dermatitis, n (%)	79 (23)	25 (18)	11 (11)	43 (40)	<.001
IgE-mediated food allergy, n (%)	53 (15)	15 (11)	5 (5)	33 (31)	<.001
Allergic rhinitis, n (%)					
Presence	161 (46)	37 (27)	35 (34)	89 (82)	<.001
Severe	59 (17)	19 (4)	6 (6)	34 (32)	
Total-IgE, mean (SD)	405 (930)	64 (4)	129 (29)	1086 (869)	<.001
Phadiatop Infant test, n (%)	161 (46)	20 (15)	35 (34)	106 (98)	<.001
Perennial sensitization only,† n (%)	69 (20)	2 (6)	16 (39)	51 (48)	<.001
Seasonal sensitization only,‡ n (%)	5 (1)	1 (3)	4 (12)	0 (0)	.002
Perennial and seasonal sensitization,§ n (%)	55 (3)	3 (11)	2 (6)	50 (52)	<.001
<i>Alternaria alternata</i> sensitization, n (%)	31 (9)	2 (6)	3 (9)	26 (29)	<.001
Peanut sensitization, n (%)	26 (7)	4 (12)	3 (10)	19 (22)	.25
Cow's milk and/or egg sensitization, n (%)	53 (15)	11 (32)	15 (44)	27 (30)	.31
Staphylococcal toxins sensitization, n (%)	63 (18)	8 (6)	4 (4)	50 (53)	<.001
Nonallergic comorbidities					
GERD, n (%)	112 (32)	64 (37)	27 (26)	21 (20)	<.001
History of pneumonia, n (%)	88 (25)	43 (31)	33 (31)	12 (11)	<.001
Annual antibiotic treatments, n (%)					<.001
0-3	274 (78)	96 (70)	79 (76)	99 (92)	
4-12	56 (16)	28 (20)	23 (22)	5 (5)	
>12	20 (6)	14 (10)	2 (2)	4 (4)	
BAL microbial cultures, n (%)					<.001
Positive bacterial culture	76 (22)	36 (26)	22 (21)	18 (17)	
<i>Haemophilus influenzae</i> ¶	18 (5)	8 (6)	9 (9)	1 (1)	
<i>Staphylococcus aureus</i> ¶	13 (4)	3 (2)	1 (1)	9 (8)	
<i>Streptococcus pneumoniae</i> ¶	11 (3)	4 (3)	4 (4)	3 (3)	
<i>Branhamella catarrhalis</i> ¶	18 (5)	12 (9)	4 (4)	2 (2)	
Other bacteria	16 (5)	9 (6)	4 (4)	3 (3)	

GERD, Gastroesophageal reflux disease.

Boldface values indicate statistical significance. Specific IgE values were positive if ≥ 0.35 kU/L.* χ^2 test when conditions were respected or the Fisher exact test otherwise.

†Perennial sensitization was defined as IgE sensitization to house dust mite and/or cat or dog dander without seasonal sensitization.

‡Seasonal sensitization was defined as unique sensitization to grass pollens and/or birch pollens without perennial sensitization.

§Perennial and seasonal sensitization was defined as IgE sensitization to house dust mite and/or cat or dog dander with seasonal sensitization.

||Total IgE is expressed in kU/L.

¶Positive bacterial culture was defined as growth $\geq 10^4$ colony-forming units (CFU)/mL.

TABLE IV. Blood and bronchoalveolar lavage inflammatory markers according to cluster analysis

	Entire population (N = 350)	Cluster 1: Neutrophilic steroid-refractory recurrent wheeze phenotype (n = 138)	Cluster 2: Severe recurrent wheeze with sensitization to a single aeroallergen (n = 104)	Cluster 3: Eosinophilic steroid-refractory asthma phenotype (n = 108)	P value*
Blood PN,† mean (SD)	4058 (2669)	4524 (3152)	4100 (2640)	3430 (1784)	.05
Blood PE,† mean (SD)	334 (355)	227 (221)	297 (422)	506 (359)	<.001
BAL PN,‡ mean (SD)	6.2 (9.6)	6.9 (10.1)	6.5 (9.5)	5.3 (9.0)	.10
BAL PE,‡ mean (SD)	1.2 (3.9)	0.5 (2.1)	0.6 (1.7)	2.6 (6.1)	<.001
IgG,§ n (%)	79 (25)	10 (8)	17 (19)	52 (52)	<.001
IgA,§ n (%)	79 (25)	16 (13)	9 (10)	54 (54)	<.001
IgM,§ n (%)	78 (25)	25 (21)	22 (25)	31 (31)	.21

Blood PE, Blood eosinophil cells; Blood PN, blood neutrophil cells; BAL, bronchoalveolar lavage.

Boldface values indicate statistical significance.

*ANOVA or χ^2 test when conditions were respected; the Kruskal-Wallis or Fisher exact test otherwise.

†Blood neutrophil absolute count and blood eosinophil absolute count are expressed as number of cells/mm³.

‡Bronchoalveolar neutrophil and eosinophil cells are expressed as percentage of total bronchoalveolar cell count.

§IgG, IgA, IgM are expressed as number of children (percentage) with values equal to or above the 75th percentile.

cells/mm³, $P = .05$) (Table IV) and can be summarized as *Neutrophilic steroid-refractory recurrent wheeze phenotype*.

Cluster 2. This cluster comprised 104 children with an average age of 4.7 years (Table II). This phenotype was severe and controlled with high-dose ICS in the majority of cases (63%, $P < .001$) (Table II). The Phadiatop Infant test was positive in 34% of the cases with sensitization to aeroallergens only (12%, $P = .002$) (Table III). These children, as in cluster 1, were more likely to have a history of pneumonia (31%, $P < .001$) compared with cluster 3 (Table III). The children in this cluster were also more likely to have attended day-care facilities before 3 years (42%, $P < .001$) compared with the other clusters (see Table E1 in this article's Online Repository at www.jaci-inpractice.org). This cluster can be summarized as *Severe recurrent wheeze with sensitization to a single aeroallergen*.

Cluster 3. This cluster comprised 108 children who were significantly older (with a mean age of 10.9 years) and had a higher BMI (above the 75th percentile) compared with the other clusters (35%, $P < .001$) (Table II). Asthma was uncontrolled despite high-dose ICS in the majority of cases (76%, $P < .001$) compared with cluster 2 (Table II). Paternal asthma was more frequently encountered in this cluster (Table II). Wheezing triggers were multiple (66%, $P < .001$) (Table II). This cluster was characterized by more allergic rhinitis (82%, $P < .001$) that was severe in 32% of cases ($P < .001$), more active atopic dermatitis (40%, $P < .001$), and more IgE-mediated food allergies (31%, $P < .001$) (Table III). The Phadiatop Infant test was positive in 98% of the cases ($P < .001$) with both perennial and seasonal sensitization in 52% ($P < .001$) (Table III). These children had more sensitization to *A. alternata* (29%, $P < .001$) (Table III) and staphylococcal toxins (53%, $P < .001$) (Table III) and see Table E2 in this article's Online Repository at www.jaci-inpractice.org. Blood atopy markers were higher in this group with a higher total-IgE (mean 1086 kU/L, $P < .001$), higher blood eosinophil count (mean 506/mm³, $P < .001$), and higher percentage of eosinophils in BAL (mean 2.6%, $P < .001$) (Table IV) but also higher IgG and IgA levels (values equal to or above the 75th percentile in 52% and 54% of cases, respectively, $P < .001$). This phenotype can be summarized as *Eosinophilic steroid-refractory asthma phenotype*.

DISCUSSION

Interpretation of findings

This article presents the detailed clinical and biological characteristics of a cohort of 350 preschool and children with both severe and moderate asthma or recurrent wheeze with BAL evaluation. To date, in the literature, only 1 European cohort of 298 children with severe or mild/moderate asthma and recurrent preschool wheeze has been described,⁹ in which the main result was impaired quality of life related to the severity of the disease. The main result of our study is that 2 phenotypes of severe asthma and severe recurrent wheeze are related to different inflammatory cells according to the allergic or nonallergic nature of the comorbidities. More specifically, comorbidities are related to: (i) a history of pneumonia or a history of GERD in younger children with steroid-refractory recurrent wheeze and (ii) multiple allergic comorbidities (especially atopic dermatitis) in steroid-refractory asthma in children. Dual cellular inflammation in the blood and BAL is related to the principal trigger, that is, neutrophilic in nonallergic steroid-refractory recurrent wheeze associated with a history of pneumonia in preschool children and eosinophilic in allergic steroid-refractory asthma with allergic triggers in children, as previously described.²⁷

Neutrophilic steroid-refractory recurrent wheeze phenotype.

This phenotype is in accordance with other studies that found neutrophilic cells in BAL in infants with recurrent wheeze.^{28,29} Several studies are also in accordance with the association of neutrophilic inflammation, bacterial infections, and wheeze, as seen in the children of our cluster 1. Neutrophilic asthma represents up to 25% of patients with symptomatic asthma and 59% of patients on high-dose ICS.³⁰ However, to date, this phenotype has only been described in adult populations, mainly with late onset asthma, rather than in children. Rackemann⁶ first recognized the possible importance of respiratory infections on the etiology of *intrinsic* (nonallergic) asthma over 60 years ago. Pathogen-host interactions have been demonstrated to lead to bronchial inflammation in asthma.³¹ Therefore, the term *intrinsic* asthma can be of clinical relevance and raises the possibility that these respiratory infections may play an important role in this asthma phenotype. Viral respiratory tract infections weaken local defences against




FIGURE 3. Representation of the 3 clusters according to blood neutrophils, blood eosinophils, and percentage of refractory asthma for the entire population ($n = 350$). Blood neutrophils and eosinophils are expressed in cells/mm³. Circled areas represent the percentage of steroid-refractory asthma or steroid-refractory recurrent wheeze defined as the percentage of severe asthma or severe recurrent wheeze, uncontrolled with high doses of inhaled corticosteroids.

opportunistic bacterial pathogens, enhancing the risk of secondary pathogens breaching mucosal barriers. The result is an amplification of immune-inflammatory responses associated with tissue damage.³² Thus, in an Australian cohort, both the respiratory syncytial virus and rhinovirus were independently associated with acute respiratory illness symptom expression, and after controlling for virus, *Haemophilus*, *Streptococcus*, and/or *Moraxella* microbial profile groups remained highly significantly associated with acute respiratory illness.³³ More specifically, a predominance of *Moraxella catarrhalis* or members of the *Haemophilus* or *Streptococcus* genera was found to be associated with a neutrophilic airway phenotype in treatment-resistant persistent asthma. In this particularly severe asthma phenotype, innate immune mechanisms may lead to a shift towards Th1- or Th17-mediated neutrophilic inflammation.³⁴ This pulmonary neutrophilic inflammation is corticosteroid refractory, as in patients with severe asthma. More recent studies^{35,36} provide clinical support to our data, suggesting that the airway microbiota in noneosinophilic (neutrophilic) asthma is different from eosinophilic phenotypes, and may be manipulated to improve clinical outcomes.

In our cluster 1, GERD was a significant nonallergic comorbidity associated with steroid-refractory recurrent wheeze that has been well described in the literature. The prevalence of GERD symptoms in patients with asthma is around 60%.³⁷ In adult populations, a higher incidence of GERD³⁸ is associated with frequent hospitalizations, poor respiratory function, and late onset disease in nonallergic asthmatic patients. In the SARP cohort,³⁹ GERD with low pH was also independently associated with high BAL neutrophil counts. A chronic, undetected infection could also play a role in the neutrophilic inflammation and low pH.⁴⁰ These subpopulations may be responsive to targeted, steroid-sparing therapy, for example, antiacid therapy and/or exercise and weight loss. In our study, GERD was encountered

in the cluster with younger children with frequent hospitalizations and neutrophil inflammation in the blood and BAL. This is the first time this phenotype, very similar to an adult phenotype, has been described in children. In a previous article,¹¹ we described a severe nonatopic phenotype, with a special trajectory during the preschool period: half of the children in this phenotype progress to moderate-to-severe allergic asthma and half to mild or episodic asthma. We thus believe that this recurrent severe wheeze phenotype is a particular phenotype that does not necessarily have a good prognosis. Nevertheless, children of cluster 2 will probably be at risk of persistent asthma during childhood due to the link of this cluster to atopy defined by the association with allergic sensitization.¹¹

Eosinophilic steroid-refractory asthma phenotype. An earlier study by our group in asthmatic children showed a link between intra-alveolar eosinophilia and atopy.²⁷ Moreover, it is known that blood eosinophilia is closely correlated to eosinophil inflammation in the deep lung tissues.⁴¹ We also found this relationship between bronchoalveolar and blood eosinophilia in the present study. Hargreave⁴² showed that measurements of sputum eosinophils can be used to guide effective corticosteroid treatment in asthma. Nevertheless, in the case of multiple allergic sensitization and/or multiple allergic comorbidities (such as atopic dermatitis or food allergy) or particular sensitization (such as staphylococcal enterotoxin), high levels of a marker of eosinophilic inflammation potentially associated with the steroid-refractory asthma phenotype have been found.⁴³ Therefore, serum staphylococcal enterotoxin-specific IgE levels have been positively associated with the severity of asthma^{44,45} particularly in late onset asthma,⁴⁶ linked to staphylococcal serine protease-like proteins⁴⁷ as “pacemakers” of allergic airway reactions to *Staphylococcus aureus*. It indirectly suggests a role of this pathogen in the etiology of airway disease and implies that pathogen-

specific IgE production and allergic-type inflammation may occur with a chronic inflammatory process.

Severe acute asthma requiring intensive care is more frequently associated with food allergy.⁴⁸ Mold sensitization in allergic asthma is associated with severe exacerbations requiring hospitalization and uncontrolled asthma despite high doses of ICS.⁴⁹ Recently, a cluster analysis applied to patients with near fatal asthma⁵⁰ described 3 clusters including 1 phenotype related to sensitization to soybean or *A. alternata*, thereby suggesting the existence of a specific pathogenic mechanism of these particular sensitizations. This cluster is very close to our cluster 3 called *Eosinophilic steroid-refractory asthma phenotype*, in which sensitization to *A. alternata* was encountered in 29% ($P < .001$) of the children. In the TAP cohort, we have already described⁵¹ that multiple allergies, defined as sensitization to both food and inhaled allergens, define a severe phenotype of asthma in terms of severity of exacerbations. Moreover, the severe allergic phenotype with atopic dermatitis is strongly associated with eosinophil-driven inflammatory markers. Recently, in a cluster analysis of 125 children, our team described 4 clusters.⁵¹ Among them, 1 cluster called *Multiple allergies and severe asthma* was characterized by atopic dermatitis in 100% of the cases, higher values of total-IgE (1123 kU/L), and high fractional exhaled nitric oxide (median value 67 ppb). This phenotype is also very close to the present cluster 3 *Eosinophilic steroid-refractory asthma phenotype*, in which atopic dermatitis is present in 43% of the cases ($P < .001$). In the 2 allergic clusters of the present study, MTW is highly prevalent. This relation between allergy and multiple triggers has been described previously.⁵² Furthermore, this association has been highlighted in a study of 551 much younger children enrolled in the TAP.⁴ We described an atopic MTW phenotype including more children with MTW (68%) than the other 2 clusters with atopic dermatitis in 75% of cases and positive Phadiatop Infant test results in 90% of the cases. A history of paternal asthma was more frequently encountered in this cluster as a genetic component of allergic asthma.⁵³

Strengths and limits of the study

The strength of the present study is that it was performed in a large and well-defined population of children with severe asthma or severe recurrent wheeze. To our knowledge, this is the first study of a cohort of children with severe recurrent preschool wheeze and severe school-age asthma, analyzed in terms of clinical, biological, and bronchial examinations.

The main limitation of our study lies in the fact that all the patients were recruited from one center. Nevertheless, whereas two-thirds of the asthmatic children were from Paris and the surrounding area (>10 million inhabitants), the remaining one-third were from regions throughout France, which limits this potential bias. A second limitation is that cluster analysis is an unsupervised analysis where the “statistical machine” clustered the data by age. Nevertheless, our results are in accordance with our previous phenotypes in preschool children⁴ and in children.⁵⁴ Thirdly, the two-dimensional representation should be carefully interpreted because a relatively small part of the total variance is explained by the first 2 components. The last limitation is that the study was cross-sectional. However, the longitudinal assessment of this SAMP cohort is ongoing, and the stability of the phenotypes we have described here will be analyzed with a longer follow-up in a future publication.

CONCLUSIONS

From this large study of children with severe asthma or severe recurrent wheeze, we describe 2 steroid-refractory phenotypes. We suggest that these phenotypes could be included in recommendations for managing severe asthma and severe recurrent wheeze in children. To optimize treatment strategies, antiallergic drugs such as anti-IgE (omalizumab) or anti-interleukin-5 could be administered to children with the phenotype *Eosinophilic steroid-refractory asthma phenotype*, whereas antineutrophil drugs such as macrolides⁵⁵ and antacid therapy could be an appropriate treatment choice for children with the phenotype *Neutrophilic steroid-refractory recurrent wheeze phenotype*.

Acknowledgments

The authors thank Marie-Ange Selva, Victoria Apetri, Ines Benhamouche, Sophie Pheng, Clarisse Peltier, Anouk Dupin, Deborah Guinot, and Nolwen Mazin for their participation and their help in this study.

REFERENCES

- Barnes PJ. Pathophysiology of allergic inflammation. *Immunol Rev* 2002;242:31-50.
- Humbert M, Menz G, Ying S, Corrigan CJ, Robinson DS, Durham SR, et al. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. *Immunol Today* 1999;20:528-33.
- Herr M, Just J, Nikasinovic L, Foucault C, Le Marec AM, Giordanela JP, et al. Risk factors and characteristics of respiratory and allergic phenotypes in early childhood. *J Allergy Clin Immunol* 2012;130:389-96.
- Just J, Gouvis-Echraghi R, Couderc R, Guillemot-Lambert N, Saint-Pierre P. Novel severe wheezy young children phenotypes: boys atopic multiple-trigger and girls nonatopic uncontrolled wheeze. *J Allergy Clin Immunol* 2012;130:103-10.
- Romanet-Manent S, Charpin D, Magnan A, Lanteaume A, Vervloet D. Allergic vs nonallergic asthma: what makes the difference? *Allergy* 2002;57:607-13.
- Rackemann FM. A working classification of asthma. *Am J Med* 1947;3:601-6.
- Beigelman A, Bacharier LB. Management of preschool children with recurrent wheezing: lessons from the NHLBI's Asthma Research Networks. *J Allergy Clin Immunol Pract* 2016;4:1-8.
- Bacharier LB, Phillips BR, Bloomberg GR, Zeiger RS, Paul IM, Krawiec M, et al. Severe intermittent wheezing in preschool children: a distinct phenotype. *J Allergy Clin Immunol* 2007;119:604-10.
- Fleming L, Murray C, Bansal AT, Hashimoto S, Bisgaard H, Bush A, et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. *Eur Respir J* 2015;46:1322-33.
- Saglan S, Payne DN, Zhu J, Wang Z, Nicholson AG, Bush A, et al. Early detection of airway wall remodeling and eosinophilic inflammation in preschool wheezers. *Am J Respir Crit Care Med* 2007;176:858-64.
- Just J, Saint-Pierre P, Gouvis-Echraghi R, Boutin B, Panayotopoulos V, Chebahi N, et al. Wheeze phenotypes in young children have different courses during the preschool period. *Ann Allergy Asthma Immunol* 2013;111:256-61.
- Fitzpatrick AM, Gaston BM, Erzurum SC, Teague WG. Features of severe asthma in school-age children: atopy and increased exhaled nitric oxide. *J Allergy Clin Immunol* 2006;118:1218-25.
- Hansbro PM, Scott GV, Essilfie AT, Kim RY, Syarkey MR, Nguyen DH, et al. Th2 cytokine antagonists: potential treatments for severe asthma. *Expert Opin Investig Drugs* 2013;22:49-69.
- Wassall HJ, Devenny AM, Daud Khan S, Ninan TK, Russell G. A comparison of virus-associated and multi-trigger wheeze in school children. *J Asthma* 2005;42:737-44.
- Campo P, Rodriguez F, Sanchez-Garcia S, Barranco P, Quirce S, Pérez-Francis C, et al. Phenotypes and endotypes of uncontrolled severe asthma: new treatments. *J Investig Allergol Clin Immunol* 2013;23:76-88.
- Global Initiative for Asthma. Pocket guide for asthma management and prevention. Available at: http://ginasthma.org/wp-content/uploads/2016/01/GINA_Pocket_2015.pdf. Accessed February 26, 2017.
- Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, et al. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. *Eur Respir J* 1995;8:483-91.
- Australasian Society of Clinical Immunology and Allergy. Skin prick testing for the diagnosis of allergic disease: a manual for practitioners. Available at: <https://>

- allergy.org.au/images/stories/pospapers/ASCIASPT_Manual_March_2016.pdf. Accessed February 26, 2017.
19. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol* 2006;101:1900-20.
 20. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med* 1987;106:196-204.
 21. Garcia J, Roure P, Hayem C, Dupont D. Bronchial endoscopy under local anesthesia and pain in children. The value of a nitrous oxide-oxygen combination. *Rev Mal Respir* 1998;15:179-83.
 22. de Blic J, Midulla F, Barbato A, Clement A, Dab I, Eber E, et al. Bronchoalveolar lavage in children. ERS Task Force on bronchoalveolar lavage in children. European Respiratory Society. *Eur Respir J* 2000;15:217-31.
 23. Baselski VS, Wunderink RG. Bronchoscopic diagnosis of pneumonia. *Clin Microbiol Rev* 1994;7:533-58.
 24. Maechler M, Rousseeuw P, Struyf A, Hubert M, Hornik K. cluster: Cluster Analysis Basics and Extensions. R package version 2.0.5. 2016. Available at: <https://cran.r-project.org/web/packages/cluster/cluster.pdf>. Accessed February 26, 2017.
 25. Kaufman L, Rousseeuw PJ. Finding Groups in Data: An Introduction to Cluster Analysis. Hoboken, NJ: John Wiley & Sons, Inc.; 2008.
 26. Pagès J. Analyse factorielle de données mixtes. *Revue Statistique Appliquée* 2002;52:93-111.
 27. Just J, Fournier L, Momas I, Zambetti C, Sahraoui F, Grimfeld A. Clinical significance of bronchoalveolar eosinophils in childhood asthma. *J Allergy Clin Immunol* 2002;110:42-4.
 28. Marguet C, Jouen-Boedes F, Dean TP, Warner JO. Bronchoalveolar cell profiles in children with asthma, infantile wheeze, chronic cough, or cystic fibrosis. *Am J Respir Crit Care Med* 1999;159(Pt 1):1533-40.
 29. Oommen A, Patel R, Browning M, Grigg J. Systemic neutrophil activation in acute preschool viral wheeze. *Arch Dis Child* 2003;88:529-31.
 30. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. *Thorax* 2002;57:875-9.
 31. Durack J, Boushey HA, Lynch SV. Airway microbiota and the implications of dysbiosis in asthma. *Curr Allergy Asthma Rep* 2016;16:52.
 32. Holt PG, Sly PD. Viral infections and atopy in asthma pathogenesis: new rationales for asthma prevention and treatment. *Nat Med* 2012;18:726-35.
 33. Teo SM, Mok D, Pham K, Kusel M, Serralha M, Troy N, et al. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. *Cell Host Microbe* 2015;17:704-15.
 34. Hadebe S, Kirstein F, Fierens K, Chen K, Drummond RA, Vautier S, et al. Microbial ligand costimulation drives neutrophilic steroid-refractory asthma. *PLoS One* 2015;10:e0134219.
 35. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. *Am J Respir Crit Care Med* 2008;177:148-55.
 36. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. *Thorax* 2013;68:322-9.
 37. Cheung TK, Lam B, Lam KF, Ip M, Ng C, Kung R, et al. Gastroesophageal reflux disease is associated with poor asthma control, quality of life, and psychological status in Chinese asthma patients. *Chest* 2009;135:1181-5.
 38. Yildiz F, Mungan D, Gemicioglu B, Yorgancioglu A, Dursun B, Oner Erkekol F, et al. Asthma phenotypes in Turkey: a multicenter cross-sectional study in adult asthmatics; PHENOTURK study. *Clin Respir J* 2017;11:210-23.
 39. Liu L, Teague WG, Erzurum S, Fitzpatrick A, Mantri S, Dweik RA, et al. Determinants of exhaled breath condensate pH in a large population with asthma. *Chest* 2011;139:328-36.
 40. Carraro S, Doherty J, Zaman K, Gainov I, Turner R, Vaughan J, et al. S-nitrosothiols regulate cell-surface pH buffering by airway epithelial cells during the human immune response to rhinovirus. *Am J Physiol Lung Cell Mol Physiol* 2006;290:L827-32.
 41. Bousquet J, Chané P, Lacoste JY, Barméon G, Ghavanian N, Enanader I, et al. Eosinophilic inflammation in asthma. *N Engl J Med* 1990;323:1033-9.
 42. Hargreave FE. Quantitative sputum cell counts as a marker of airway inflammation in clinical practice. *Curr Opin Allergy Clin Immunol* 2007;7:102-6.
 43. Deschildre A, Marguet C, Salleron J, Pin I, Rittié JL, Derelle J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. *Eur Respir J* 2013;42:1224-33.
 44. Bachert C, Gevaert P, Howarth P, Holtappels G, van Cauwenberge P, Johansson SG. IgE to *Staphylococcus aureus* enterotoxins in serum is related to severity of asthma. *J Allergy Clin Immunol* 2003;111:1131-2.
 45. Tanaka A, Suzuki S, Ohta S, Manabe R, Furukawa H, Kuwahara N, et al. Association between specific IgE to *Staphylococcus aureus* enterotoxins A and B and asthma control. *Ann Allergy Asthma Immunol* 2015;115:191-7.
 46. Song WJ, Sintobin I, Sohn KH, Kang MG, Park HK, Jo EJ, et al. Staphylococcal enterotoxin IgE sensitization in late-onset severe eosinophilic asthma in the elderly. *Clin Exp Allergy* 2016;46:411-21.
 47. Stentzel S, Teufelberger A, Nordengrun M, Kolata J, Schmidt F, van Crombruggen K, et al. Staphylococcal serine protease-like proteins are pace-makers of allergic airway reactions to *Staphylococcus aureus*. *J Allergy Clin Immunol* 2017;139:432-500.
 48. Roberts G, Patel N, Levi-Schaffer F, Habibi P, Lack G. Food allergy as a risk factor for life-threatening asthma in childhood: a case-controlled study. *J Allergy Clin Immunol* 2003;112:168-74.
 49. O'Driscoll BR, Hopkinson LC, Denning DW. Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions. *BMC Pulm Med* 2005;5:4.
 50. Serrano-Pariente J, Rodrigo G, Fiz JA, Crespo A, Plaza V. Identification and characterization of near-fatal asthma phenotypes by cluster analysis. *Allergy* 2015;70:1139-47.
 51. Just J, Saint-Pierre P, Gouvis-Echraghi R, Laoudi Y, Roufai L, Amnesi Maesano I, et al. Childhood allergic asthma is not a single phenotype. *J Pediatr* 2014;164:815-20.
 52. Spycher BD, Silverman M, Pescatore AM, Beardsmore CS, Kuehni CE. Comparison of phenotypes of childhood wheeze and cough in 2 independent cohorts. *J Allergy Clin Immunol* 2015;132:1058-67.
 53. Gupta J, Johansson E, Bernstein JA, Chakraborty R, Khurana Hershey GK, Rothenberg ME, et al. Resolving the etiology of atopic disorders by using genetic analysis of racial ancestry. *J Allergy Clin Immunol* 2016;138:676-99.
 54. Just J, Gouvis-Echraghi R, Rouve S, Wanin S, Moreau D, Annesi-Maesano I. Two novel, severe asthma phenotypes identified during childhood using a clustering approach. *Eur Respir J* 2012;40:55-60.
 55. Bacharier LB, Guilbert TW, Mauger DT, Boehmer S, Beigelman A, Fitzpatrick AM, et al. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial. *JAMA* 2016;314:2034-44.

ONLINE REPOSITORY

Materials and Methods

Study design. Exclusion criteria were: (i) chronic obstructive pulmonary disease (congenital or acquired origin) other than asthma; (ii) prematurity; and (iii) an exacerbation or acute respiratory illness at the time of exploration.

Atopic status. The maternal and paternal history of asthma was collected. Allergic rhinitis and active atopic dermatitis were assessed by questions from the International Study of Asthma and Allergies in Childhood (ISAAC),^{E1} and IgE-mediated food allergy was defined by relevant symptoms of food allergy within the 6 hours after food allergen's consumption associated with an allergic sensitization to the same allergen.^{E2}

Biological markers of atopy were measured in peripheral blood. These included: (i) less-specific markers such as blood eosinophilia (cell counting by automated Sysmex, France); (ii) total-IgE (measured by ImmunoCAP; Phadia, Uppsala, Sweden); (iii) allergenic sensitization to aeroallergens and food allergens defined as a positive skin-prick test (SPT) (wheat allergen ≥ 3 mm in the absence of a positive reaction to the negative control), and confirmed by positive specific IgE (≥ 0.35 kU/L) (ImmunoCAP; Phadia, Uppsala, Sweden). The allergens assessed were house dust mites (HDM), cat and dog dander, grass and birch pollens, cow's milk proteins, egg, and peanut. Specific IgE to *Alternaria alternata* and staphylococcal toxins (A, B, C, toxic shock syndrome toxin-1) were also analyzed. The Phadiatop Infant test (ImmunoCAP; Phadia, Uppsala, Sweden) was assessed in all children and a result ≥ 0.35 kU/L was considered positive.^{E3} We defined sensitization as positive SPT as well as positive specific IgE to ensure an accurate diagnosis.

Perennial sensitization only was defined as sensitization to HDM and/or cat or dog dander without seasonal sensitization. Seasonal sensitization was defined as sensitization to grass and/or birch pollens only without perennial sensitization.

Flexible bronchoscopy. Flexible bronchoscopy was performed under local anesthesia as previously described in our center in which more than 300 flexible bronchoscopies are routinely performed a year.^{E4} Children received intrarectal midazolam and atropine with nitrous oxide (Entonox) during the bronchoscopy. Bronchoalveolar lavage (BAL) was obtained as per European Respiratory Society guidelines^{E5} and processed for cytology by the hospital cytopathology department. Total cell

count was expressed as an absolute rate. Eosinophil and neutrophil cells were expressed in percentage of the total cell count.

Inflammatory markers. Nonspecific inflammatory markers were measured in peripheral blood. These included neutrophil counts expressed in absolute rate per mm³ (cell counting by automated Sysmex; Roche Diagnostics, Roissy, France), serum IgG, IgA and IgM levels (g/L) using the immunoturbidimetry technique (PLC Modular; Roche Diagnostics, Meylan, France) and percentage of eosinophil and neutrophil cells in BAL.

Variable reduction and data transformation. The initial dataset provided almost 100 variables selected from a large spectrum of routine assessments of asthmatic children. The following *a priori* strategies were used to reduce the number of variables before performing the cluster analysis. Selecting variables reflecting major physiological parameters reduced the number of variables that were clinically redundant. Spectra of response variables were transformed into "composite variables"; for example, perennial sensitization only was defined as sensitization to HDM and/or cat or dog dander without seasonal sensitization, or sensitization to grass and/or birch pollens only without perennial sensitization defined as seasonal sensitization.

In the end, 34 variables were included in the cluster analysis: (1) age at the time of exploration; (2) age of asthma onset; (3) >75th percentile BMI; (4) gender; (5) parents' socio-professional categories; (6) ethnic group; (7) maternal history of asthma; (8) paternal history of asthma; (9) history of pneumonia; (10) history of GERD; (11) active allergic rhinitis; (12) active atopic dermatitis; (13) IgE-mediated food allergy; (14) more than 2 hospitalizations for severe exacerbation during the previous year; (15) wheezing triggers; (16) annual number of antibiotics for pneumonia; (17) asthma severity; (18) perennial sensitization only; (19) seasonal sensitization only; (20) both sensitization to perennial and seasonal allergens; (21) sensitization to egg and/or cow's milk proteins; (22) peanut sensitization; (23) *A. alternata* sensitization; (24) staphylococcal toxin sensitization; (25) Phadiatop Infant test ≥ 0.35 kU/L; (26) absolute value of blood neutrophil; (27) absolute value of blood eosinophil; (28) serum total IgE (kU/L); (29) IgG level (g/L); (30) IgA level (g/L); (31) IgM level (g/L); (32) BAL neutrophil percentage; (33) BAL eosinophil percentage; (34) BAL microbiological cultures.

TABLE E1. Environmental exposure associated with cluster phenotypes

	Entire population (N = 350)	Cluster 1: Neutrophilic steroid-refractory recurrent wheeze phenotype (n = 138)	Cluster 2: Severe recurrent wheeze with sensitization to a single aeroallergen (n = 104)	Cluster 3: Eosinophilic steroid-refractory asthma phenotype (n = 108)	P value*
Tobacco smoke exposure, n (%)	118 (34)	53 (38)	31 (30)	34 (31)	NS
Molds, n (%)	76 (22)	27 (19)	24 (23)	25 (23)	NS
Cockroaches, n (%)	23 (7)	6 (4)	10 (10)	7 (6)	NS
Daycare attendance, n (%)	122 (35)	52 (38)	43 (42)	27 (25)	.03
Overcrowding, n (%)	31 (9)	8 (6)	12 (12)	11 (10)	NS

NS, Nonsignificant.

Boldface values indicate statistical significance.

* χ^2 test when conditions allowed or Fisher's exact test otherwise.

TABLE E2. Staphylococcal toxin sensitization according to cluster analysis

	Entire population (N = 350)	Cluster 1: Neutrophilic steroid-refractory recurrent wheeze phenotype (n = 138)	Cluster 2: Severe recurrent wheeze with sensitization to a single aeroallergen (n = 104)	Cluster 3: Eosinophilic steroid-refractory asthma phenotype (n = 108)	P value*
Staphylococcal toxin sensitization, n (%)					<.001
Absence	249 (79)	109 (92)	94 (96)	46 (48)	
A toxin	23 (7)	6 (5)	2 (2)	15 (16)	
B toxin	20 (6)	2 (2)	2 (2)	16 (17)	
C toxin	15 (5)	0 (0)	0 (0)	15 (16)	
TSST toxin	5 (2)	1 (1)	0 (0)	4 (4)	

TSST, Toxic shock syndrome toxin-1.

Boldface values indicate statistical significance.

All IgE values were positive if ≥ 0.35 kU/L.* χ^2 test when conditions allowed or Fisher's exact test otherwise.**REFERENCES**

- E1. Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, et al. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. *Eur Respir J* 1995;8:483-91.
- E2. Australasian Society of Clinical Immunology and Allergy. Skin prick testing for the diagnosis of allergic disease: a manual for practitioners. Available at: https://allergy.org.au/images/stories/pospapers/ASCIASPT_Manual_March_2016.pdf. Accessed February 26, 2017.
- E3. Bernstein IL, Storms WW. Practice parameters for allergy diagnostic testing. Joint Task Force on Practice Parameters for the Diagnosis and Treatment of Asthma. The American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. *Ann Allergy Asthma Immunol* 1995;75(Pt 2):543-625.
- E4. Garcia J, Roure P, Hayem C, Dupont D. Bronchial endoscopy under local anesthesia and pain in children. The value of a nitrous oxide-oxygen combination. *Rev Mal Respir* 1998;15:179-83.
- E5. de Blic J, Midulla F, Barbato A, Clement A, Dab I, Eber E, et al. Bronchoalveolar lavage in children. ERS Task Force on bronchoalveolar lavage in children. European Respiratory Society. *Eur Respir J* 2000;15:217-31.